Free Trial

Viridian Therapeutics (VRDN) Competitors

Viridian Therapeutics logo
$18.01 -0.86 (-4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$18.00 -0.01 (-0.06%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRDN vs. RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, PRVA, VCYT, and HTFL

Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), Veracyte (VCYT), and Heartflow (HTFL). These companies are all part of the "healthcare" industry.

Viridian Therapeutics vs. Its Competitors

Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$300K4,902.92-$269.95M-$3.83-4.70
RadNet$1.91B3.02$2.79M-$0.20-374.95

In the previous week, RadNet had 7 more articles in the media than Viridian Therapeutics. MarketBeat recorded 13 mentions for RadNet and 6 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.65 beat RadNet's score of 1.13 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
RadNet
8 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.9% of RadNet shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 5.6% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Viridian Therapeutics currently has a consensus price target of $37.78, indicating a potential upside of 109.76%. RadNet has a consensus price target of $76.80, indicating a potential upside of 2.41%. Given Viridian Therapeutics' higher probable upside, research analysts clearly believe Viridian Therapeutics is more favorable than RadNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
RadNet
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.25

Viridian Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-112,806.88% -78.95% -49.91%
RadNet -0.78%2.41%0.82%

Summary

RadNet beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRDN vs. The Competition

MetricViridian TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.47B$3.10B$5.74B$10.24B
Dividend YieldN/A2.32%5.69%4.59%
P/E Ratio-4.7021.3874.9326.41
Price / Sales4,902.92244.04457.2789.16
Price / CashN/A44.4425.8129.91
Price / Book2.969.6413.256.28
Net Income-$269.95M-$53.20M$3.29B$270.38M
7 Day Performance-9.09%0.44%0.47%2.70%
1 Month Performance-2.86%4.26%4.60%5.99%
1 Year Performance-18.36%9.43%73.42%25.94%

Viridian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRDN
Viridian Therapeutics
2.2602 of 5 stars
$18.01
-4.6%
$37.78
+109.8%
-14.5%$1.47B$300K-4.7050Positive News
RDNT
RadNet
3.3717 of 5 stars
$71.99
+0.8%
$76.80
+6.7%
+9.2%$5.49B$1.83B-359.9311,021Positive News
Insider Trade
OPCH
Option Care Health
4.8742 of 5 stars
$29.59
+1.7%
$35.75
+20.8%
-11.0%$4.72B$5.00B23.678,088Positive News
SHC
Sotera Health
2.1749 of 5 stars
$15.91
+1.9%
$16.00
+0.6%
-4.5%$4.44B$1.10B198.903,000High Trading Volume
BTSG
BrightSpring Health Services
2.2923 of 5 stars
$25.48
+5.6%
$25.67
+0.7%
+91.0%$4.27B$11.27B82.2035,000High Trading Volume
WGS
GeneDx
2.7288 of 5 stars
$129.33
-2.4%
$101.63
-21.4%
+227.3%$3.81B$305.45M2,586.601,200
CON
Concentra Group Holdings Parent
3.0999 of 5 stars
$22.79
-1.3%
$27.50
+20.7%
-4.0%$2.96B$1.90B19.1511,250Positive News
SGRY
Surgery Partners
3.1579 of 5 stars
$22.08
-1.9%
$33.00
+49.5%
-29.5%$2.89B$3.11B-15.4415,000News Coverage
Positive News
PRVA
Privia Health Group
4.4218 of 5 stars
$23.59
+1.3%
$28.58
+21.2%
+20.3%$2.86B$1.74B214.471,140Positive News
VCYT
Veracyte
3.7554 of 5 stars
$32.46
+0.1%
$40.90
+26.0%
-6.2%$2.55B$445.76M98.37790
HTFL
Heartflow
N/A$34.50
+11.0%
$35.80
+3.8%
N/A$2.52BN/A0.00699Quiet Period Expiration
Gap Up

Related Companies and Tools


This page (NASDAQ:VRDN) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners